No Data
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Merck & Co Unusual Options Activity For March 10
Genmab Announces Johnson & Johnson Has Decided That It Will Not Exercise Its Option To Receive A Worldwide License To Develop, Manufacture And Commercialize HexaBody-CD38; Genmab Will Not Pursue Further Clinical Development
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Weight-loss Drug Battle: Who Are the Latest Players Involved